<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 78-year-old male with <z:hpo ids='HP_0005584'>renal carcinoma</z:hpo> was treated with a high dose infusion of interferon-alpha (IFN-alpha) for eight months </plain></SENT>
<SENT sid="1" pm="."><plain>The patient had evidence of <z:e sem="disease" ids="C0029221" disease_type="Mental or Behavioral Dysfunction" abbrv="">organic brain syndrome</z:e> such as dysfunction of memory, slowing of behavior, and development of mental <z:hpo ids='HP_0001289'>confusion</z:hpo> that appeared eight months after the treatment </plain></SENT>
<SENT sid="2" pm="."><plain>MRI at the time of mental <z:hpo ids='HP_0001289'>confusion</z:hpo> revealed diffuse white matter lesions </plain></SENT>
<SENT sid="3" pm="."><plain>Neuropathologic findings were compatible to <z:e sem="disease" ids="C0270786" disease_type="Disease or Syndrome" abbrv="">Binswanger's disease</z:e> and Senile <z:hpo ids='HP_0000726'>Dementia</z:hpo> of Alzheimer Type (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SDAT</z:e>), Preexisting <z:hpo ids='HP_0000707'>neurologic abnormalities</z:hpo> including intracerebral <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> and <z:hpo ids='HP_0002059'>cerebral atrophy</z:hpo> may increase susceptibility to unacceptably severe IFN neurotoxicity </plain></SENT>
</text></document>